Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases

Fig. 4

UC-MSCs’ biological activity in vitro after pro-inflammatory priming. A IDO expression (%) at basal state (NT) and after pro-inflammatory priming by IFNγ, TNFα, IFNγ + TNFα, IL1β, IL6, GM-CSF and Mix. B ICAM-1/CD54, PD-L1/CD274, VCAM-1/CD106, CD200, IFNγ-R/CD119, TNFα-RII/CD120b expression (%) at basal state (NT) and after pro-inflammatory priming by IFNγ, TNFα and IFNγ + TNFα. C T-lymphocyte proliferation (%) at ratio UC-MSCs:PBMC 0:1, 1:10, 1:30, 1:100, 1:300 and 1:1000 at basal state (NT) and after pro-inflammatory priming by IFNγ, TNFα and IFNγ + TNFα. */$p < 0.05, **/$$p < 0.01, ***/$$$p < 0.001, ****/$$$$p < 0.0001. n = 3 batches from 1 UC

Back to article page